1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Virology
  4. Volume 6, 2019
  5. Article

Annual Review of Virology

Volume 6, 2019

Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Abstract

The recent market approvals of recombinant adeno-associated virus (rAAV) gene therapies in Europe and the United States are landmark achievements in the history of modern science. These approvals are also anticipated to herald the emergence of a new class of therapies for monogenic disorders, which had hitherto been considered untreatable. These events can be viewed as stemming from the convergence of several important historical trends: the study of basic virology, the development of genomic technologies, the imperative for translational impact of National Institutes of Health–funded research, and the development of economic models for commercialization of rare disease therapies. In this review, these historical trends are described and the key developments that have enabled clinical rAAV gene therapies are discussed, along with an overview of the current state of the field and future directions.

Keyword(s): AAV, adeno-associated virus, clinical trial, gene therapy, genetic disease, genome editing
Loading

Article metrics loading...

/content/journals/10.1146/annurev-virology-092818-015530
2019-09-29
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/virology/6/1/annurev-virology-092818-015530.html?itemId=/content/journals/10.1146/annurev-virology-092818-015530&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Atchison RW, Casto BC, Hammon WM 1966. Electron microscopy of adenovirus-associated virus (AAV) in cell cultures. Virology 29:353–57
     [Google Scholar]
  2. 2. 
    Blacklow NR, Hoggan MD, Kapikian AZ, Austin JB, Rowe WP 1968. Epidemiology of adenovirus-associated virus infection in a nursery population. Am. J. Epidemiol. 88:368–78
     [Google Scholar]
  3. 3. 
    Blacklow NR, Hoggan MD, Rowe WP 1967. Isolation of adenovirus-associated viruses from man. PNAS 58:1410–15
     [Google Scholar]
  4. 4. 
    Blacklow NR, Hoggan MD, Sereno MS, Brandt CD, Kim HW et al. 1971. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am. J. Epidemiol. 94:359–66
     [Google Scholar]
  5. 5. 
    Schmidt OW, Cooney MK, Foy HM 1975. Adeno-associated virus in adenovirus type 3 conjunctivitis. Infect. Immun. 11:1362–70
     [Google Scholar]
  6. 6. 
    Hauswirth WW, Berns KI. 1977. Origin and termination of adeno-associated virus DNA replication. Virology 78:488–99
     [Google Scholar]
  7. 7. 
    Berns KI, Pinkerton TC, Thomas GF, Hoggan MD 1975. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 68:556–60
     [Google Scholar]
  8. 8. 
    Kotin RM, Linden RM, Berns KI 1992. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 11:5071–78
     [Google Scholar]
  9. 9. 
    Kotin RM, Menninger JC, Ward DC, Berns KI 1991. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 10:831–34
     [Google Scholar]
  10. 10. 
    Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L et al. 1990. Site-specific integration by adeno-associated virus. PNAS 87:2211–15
     [Google Scholar]
  11. 11. 
    Srivastava A, Lusby EW, Berns KI 1983. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45:555–64
     [Google Scholar]
  12. 12. 
    Laughlin CA, Tratschin JD, Coon H, Carter BJ 1983. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 23:65–73
     [Google Scholar]
  13. 13. 
    Samulski RJ, Berns KI, Tan M, Muzyczka N 1982. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. PNAS 79:2077–81
     [Google Scholar]
  14. 14. 
    Samulski RJ, Srivastava A, Berns KI, Muzyczka N 1983. Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell 33:135–43
     [Google Scholar]
  15. 15. 
    Samulski RJ, Chang LS, Shenk T 1987. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61:3096–101
     [Google Scholar]
  16. 16. 
    Samulski RJ, Chang LS, Shenk T 1989. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J. Virol. 63:3822–28
     [Google Scholar]
  17. 17. 
    Flotte TR, Afione SA, Solow R, Drumm ML, Markakis D et al. 1993. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268:3781–90
     [Google Scholar]
  18. 18. 
    Egan M, Flotte T, Afione S, Solow R, Zeitlin PL et al. 1992. Defective regulation of outwardly rectifying Cl− channels by protein kinase A corrected by insertion of CFTR. Nature 358:581–84
     [Google Scholar]
  19. 19. 
    Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R et al. 1993. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. PNAS 90:10613–17
     [Google Scholar]
  20. 20. 
    Flotte T, Carter B, Conrad C, Guggino W, Reynolds T et al. 1996. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum. Gene Ther. 7:1145–59
     [Google Scholar]
  21. 21. 
    Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P et al. 2003. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther. 14:1079–88
     [Google Scholar]
  22. 22. 
    Fisher KJ, Kelley WM, Burda JF, Wilson JM 1996. A novel adenovirus–adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum. Gene Ther. 7:2079–87
     [Google Scholar]
  23. 23. 
    McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ 1996. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 713:99–107
     [Google Scholar]
  24. 24. 
    Xiao X, Li J, McCown TJ, Samulski RJ 1997. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp. Neurol. 144:113–24
     [Google Scholar]
  25. 25. 
    Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC et al. 1996. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. PNAS 93:14082–87
     [Google Scholar]
  26. 26. 
    Gao GP, Qu G, Faust LZ, Engdahl RK, Xiao W et al. 1998. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum. Gene Ther. 9:2353–62
     [Google Scholar]
  27. 27. 
    Johnston J, Tazelaar J, Rivera VM, Clackson T, Gao GP, Wilson JM 2003. Regulated expression of erythropoietin from an AAV vector safely improves the anemia of β-thalassemia in a mouse model. Mol. Ther. 7:493–97
     [Google Scholar]
  28. 28. 
    Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM et al. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. PNAS 94:5804–9
     [Google Scholar]
  29. 29. 
    Monahan PE, Samulski RJ, Tazelaar J, Xiao X, Nichols TC et al. 1998. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 5:40–49
     [Google Scholar]
  30. 30. 
    Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT et al. 2004. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum. Gene Ther. 15:93–128
     [Google Scholar]
  31. 31. 
    Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT et al. 2006. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 αl-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17:1177–86
     [Google Scholar]
  32. 32. 
    Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW et al. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8:148–54
     [Google Scholar]
  33. 33. 
    During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P et al. 1998. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 5:820–27
     [Google Scholar]
  34. 34. 
    Bankiewicz KS, Leff SE, Nagy D, Jungles S, Rokovich J et al. 1997. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp. Neurol. 144:147–56
     [Google Scholar]
  35. 35. 
    Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M et al. 2002. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 13:1391–412
     [Google Scholar]
  36. 36. 
    Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH et al. 2012. Long-term follow-up after gene therapy for Canavan disease. Sci. Transl. Med. 4:165ra3
     [Google Scholar]
  37. 37. 
    Li J, Wang D, Qian S, Chen Z, Zhu T, Xiao X 2003. Efficient and long-term intracardiac gene transfer in δ-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther 10:1807–13
     [Google Scholar]
  38. 38. 
    Beck SE, Jones LA, Chesnut K, Walsh SM, Reynolds TC et al. 1999. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J. Virol. 73:9446–55
     [Google Scholar]
  39. 39. 
    Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W et al. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76:791–801
     [Google Scholar]
  40. 40. 
    Wang Z, Zhu T, Qiao C, Zhou L, Wang B et al. 2005. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23:321–28
     [Google Scholar]
  41. 41. 
    Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. PNAS 99:11854–59
     [Google Scholar]
  42. 42. 
    Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R et al. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78:6381–88
     [Google Scholar]
  43. 43. 
    Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF et al. 2006. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14:45–53
     [Google Scholar]
  44. 44. 
    Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA et al. 2006. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99:e3–9
     [Google Scholar]
  45. 45. 
    Cearley CN, Wolfe JH. 2006. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13:528–37
     [Google Scholar]
  46. 46. 
    Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK 2009. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27:59–65
     [Google Scholar]
  47. 47. 
    Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M et al. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74:8635–47
     [Google Scholar]
  48. 48. 
    Wang RL, McLaughlin T, Cossette T, Tang Q, Foust K et al. 2009. Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of α-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17:81–87
     [Google Scholar]
  49. 49. 
    Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. 2004. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol. 78:6595–609
     [Google Scholar]
  50. 50. 
    Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N et al. 2008. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16:1252–60
     [Google Scholar]
  51. 51. 
    Koerber JT, Jang JH, Schaffer DV 2008. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 16:1703–9
     [Google Scholar]
  52. 52. 
    Stiefelhagen M, Sellner L, Kleinschmidt JA, Jauch A, Laufs S et al. 2008. Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6:12
     [Google Scholar]
  53. 53. 
    Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C et al. 2009. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. PNAS 106:3946–51
     [Google Scholar]
  54. 54. 
    Li W, Zhang L, Johnson JS, Zhijian W, Grieger JC et al. 2009. Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol. Ther. 17:2067–77
     [Google Scholar]
  55. 55. 
    Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H et al. 2010. Directed evolution of adeno-associated virus for glioma cell transduction. J. Neurooncol. 96:337–47
     [Google Scholar]
  56. 56. 
    Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC et al. 2014. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506:382–86
     [Google Scholar]
  57. 57. 
    Santiago-Ortiz J, Ojala DS, Westesson O, Weinstein JR, Wong SY et al. 2015. AAV ancestral reconstruction library enables selection of broadly infectious viral variants. Gene Ther 22:934–46
     [Google Scholar]
  58. 58. 
    Zinn E, Pacouret S, Khaychuk V, Turunen HT, Carvalho LS et al. 2015. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep 12:1056–68
     [Google Scholar]
  59. 59. 
    Li S, Ling C, Zhong L, Li M, Su Q et al. 2015. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23:1867–76
     [Google Scholar]
  60. 60. 
    Ling C, Lu Y, Kalsi JK, Jayandharan GR, Li B et al. 2010. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum. Gene Ther. 21:1741–47
     [Google Scholar]
  61. 61. 
    Li J, Samulski RJ, Xiao X 1997. Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 71:5236–43
     [Google Scholar]
  62. 62. 
    Xiao X, Li J, Samulski RJ 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72:2224–32
     [Google Scholar]
  63. 63. 
    Grimm D, Kern A, Rittner K, Kleinschmidt JA 1998. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9:2745–60
     [Google Scholar]
  64. 64. 
    Grimm D, Kay MA, Kleinschmidt JA 2003. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7:839–50
     [Google Scholar]
  65. 65. 
    Yang Q, Chen F, Trempe JP 1994. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J. Virol. 68:4847–56
     [Google Scholar]
  66. 66. 
    Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR 1995. Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6:1329–41
     [Google Scholar]
  67. 67. 
    Urabe M, Ding C, Kotin RM 2002. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13:1935–43
     [Google Scholar]
  68. 68. 
    Smith RH, Levy JR, Kotin RM 2009. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol. Ther. 17:1888–96
     [Google Scholar]
  69. 69. 
    Conway JE, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ 1997. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71:8780–89
     [Google Scholar]
  70. 70. 
    Conway JE, Rhys CM, Zolotukhin I, Zolotukhin S, Muzyczka N et al. 1999. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 6:986–93
     [Google Scholar]
  71. 71. 
    Thomas DL, Wang L, Niamke J, Liu J, Kang W et al. 2009. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum. Gene Ther. 20:861–70
     [Google Scholar]
  72. 72. 
    Conrad CK, Allen SS, Afione SA, Reynolds TC, Beck SE et al. 1996. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 3:658–68
     [Google Scholar]
  73. 73. 
    Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R et al. 1996. In vivo model of adeno-associated virus vector persistence and rescue. J. Virol. 70:3235–41
     [Google Scholar]
  74. 74. 
    Flotte TR, Afione SA, Zeitlin PL 1994. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am. J. Respir. Cell Mol. Biol. 11:517–21
     [Google Scholar]
  75. 75. 
    Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ et al. 1998. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 351:1702–3
     [Google Scholar]
  76. 76. 
    Wagner JA, Moran ML, Messner AH, Daifuku R, Conrad CK et al. 1998. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum. Gene Ther. 9:889–909
     [Google Scholar]
  77. 77. 
    Wagner JA, Messner AH, Moran ML, Daifuku R, Kouyama K et al. 1999. Safety and biological efficacy of an adeno-associated virus vector–cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109:266–74
     [Google Scholar]
  78. 78. 
    Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP et al. 2002. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum. Gene Ther. 13:1349–59
     [Google Scholar]
  79. 79. 
    Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB 2005. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum. Gene Ther. 16:921–28
     [Google Scholar]
  80. 80. 
    Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR et al. 2001. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12:1907–16
     [Google Scholar]
  81. 81. 
    Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB et al. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24:257–61
     [Google Scholar]
  82. 82. 
    Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW et al. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963–72
     [Google Scholar]
  83. 83. 
    Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW et al. 2012. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119:3038–41
     [Google Scholar]
  84. 84. 
    Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12:342–47
     [Google Scholar]
  85. 85. 
    Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T 2013. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24:59–67
     [Google Scholar]
  86. 86. 
    Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ et al. 2007. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110:2334–41
     [Google Scholar]
  87. 87. 
    Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD et al. 2009. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 119:1688–95
     [Google Scholar]
  88. 88. 
    Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J et al. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365:2357–65
     [Google Scholar]
  89. 89. 
    Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P et al. 2014. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371:1994–2004
     [Google Scholar]
  90. 90. 
    Weber A, Engelmaier A, Voelkel D, Pachlinger R, Scheiflinger F et al. 2018. Development of methods for the selective measurement of the single amino acid exchange variant coagulation factor IX Padua. Mol. Ther. Methods Clin. Dev. 10:29–37
     [Google Scholar]
  91. 91. 
    McIntosh J, Lenting P, Rosales C, Lee D, Rabbanian, et al. 2013. Therapeutic levels of FVIII following single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121:173335–44
     [Google Scholar]
  92. 92. 
    Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S et al. 2008. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. PNAS 105:15112–17
     [Google Scholar]
  93. 93. 
    Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F et al. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358:2240–48
     [Google Scholar]
  94. 94. 
    Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R et al. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358:2231–39
     [Google Scholar]
  95. 95. 
    Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB et al. 2008. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19:979–90
     [Google Scholar]
  96. 96. 
    Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF et al. 2017. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849–60
     [Google Scholar]
  97. 97. 
    Hinderer C, Katz N, Buza EL, Dyer C, Goode T et al. 2018. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29:285–98
     [Google Scholar]
  98. 98. 
    Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM 2018. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol. Ther. 26:664–68
     [Google Scholar]
  99. 99. 
    Carpentier AC, Frisch F, Labbe SM, Gagnon R, de Wal J et al. 2012. Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J. Clin. Endocrinol. Metab. 97:1635–44
     [Google Scholar]
  100. 100. 
    Gaudet D, Methot J, Dery S, Brisson D, Essiembre C et al. 2013. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20:361–69
     [Google Scholar]
  101. 101. 
    Ferreira V, Twisk J, Kwikkers K, Aronica E, Brisson D et al. 2014. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum. Gene Ther. 25:180–88
     [Google Scholar]
  102. 102. 
    Gaudet D, Stroes ES, Methot J, Brisson D, Tremblay K et al. 2016. Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Hum. Gene Ther. 27:916–25
     [Google Scholar]
  103. 103. 
    Song S, Morgan M, Ellis T, Poirier A, Chesnut K et al. 1998. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. PNAS 95:14384–88
     [Google Scholar]
  104. 104. 
    Song S, Scott-Jorgensen M, Wang J, Poirier A, Crawford J et al. 2002. Intramuscular administration of recombinant adeno-associated virus 2 α-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol. Ther. 6:329–35
     [Google Scholar]
  105. 105. 
    Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M et al. 2009. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. PNAS 106:16363–68
     [Google Scholar]
  106. 106. 
    Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R et al. 2011. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum. Gene Ther. 22:1239–47
     [Google Scholar]
  107. 107. 
    Mueller C, Gernoux G, Gruntman AM, Borel F, Reeves EP et al. 2017. 5 year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol. Ther. 25:1387–94
     [Google Scholar]
  108. 108. 
    Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B et al. 2013. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J. Clin. Invest. 123:5310–18
     [Google Scholar]
  109. 109. 
    Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR et al. 2017. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377:1713–22
     [Google Scholar]
  110. 110. 
    Borel F, Gernoux G, Sun H, Stock R, Blackwood M et al. 2018. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 10:eaau6414
     [Google Scholar]
  111. 111. 
    Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV et al. 2008. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19:463–74
     [Google Scholar]
  112. 112. 
    Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K et al. 2014. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 25:506–16
     [Google Scholar]
  113. 113. 
    Lee NC, Chien YH, Hu MH, Liu WS, Chen PW et al. 2014. Treatment of congenital neurotransmitter deficiencies by intracerebral ventricular injection of an adeno-associated virus serotype 9 vector. Hum. Gene Ther. 25:189–98
     [Google Scholar]
  114. 114. 
    Lee NC, Muramatsu S, Chien YH, Liu WS, Wang WH et al. 2015. Benefits of neuronal preferential systemic gene therapy for neurotransmitter deficiency. Mol. Ther. 23:1572–81
     [Google Scholar]
  115. 115. 
    Ahmed SS, Li H, Cao C, Sikoglu EM, Denninger AR et al. 2013. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS gene therapy in Canavan mice. Mol. Ther. 21:2136–47
     [Google Scholar]
  116. 116. 
    Gessler DJ, Li D, Xu H, Su Q, Sanmiguel J et al. 2017. Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease. JCI Insight 2:e90807
     [Google Scholar]
  117. 117. 
    Gray-Edwards HL, Regier DS, Shirley JL, Randle AN, Salibi N et al. 2017. Novel biomarkers of human GM1 gangliosidosis reflect the clinical efficacy of gene therapy in a feline model. Mol. Ther. 25:892–903
     [Google Scholar]
  118. 118. 
    Gray-Edwards HL, Brunson BL, Holland M, Hespel AM, Bradbury AM et al. 2015. Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy. Mol. Genet. Metab. 116:80–87
     [Google Scholar]
  119. 119. 
    Rockwell HE, McCurdy VJ, Eaton SC, Wilson DU, Johnson AK et al. 2015. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system. ASN Neuro 7:21759091415569908
     [Google Scholar]
  120. 120. 
    Bradbury AM, Gray-Edwards HL, Shirley JL, McCurdy VJ, Colaco AN et al. 2015. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease. Exp. Neurol. 263:102–12
     [Google Scholar]
  121. 121. 
    Golebiowski D, van der Bom IMJ, Kwon CS, Miller AD, Petrosky K et al. 2017. Direct intracranial injection of AAVrh8 encoding monkey β-N-acetylhexosaminidase causes neurotoxicity in the primate brain. Hum. Gene Ther. 28:510–22
     [Google Scholar]
  122. 122. 
    Gray-Edwards HL, Randle AN, Maitland SA, Benatti HR, Hubbard SM et al. 2018. Adeno-associated virus gene therapy in a sheep model of Tay-Sachs disease. Hum. Gene Ther. 29:312–26
     [Google Scholar]
  123. 123. 
    Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S et al. 2010. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther. 18:1731–35
     [Google Scholar]
  124. 124. 
    Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ et al. 2009. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73:1662–69
     [Google Scholar]
  125. 125. 
    Alves S, Fol R, Cartier N 2016. Gene therapy strategies for Alzheimer's disease: an overview. Hum. Gene Ther. 27:100–7
     [Google Scholar]
  126. 126. 
    Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N 2016. Adeno-associated virus-based gene therapy for CNS diseases. Hum. Gene Ther. 27:478–96
     [Google Scholar]
  127. 127. 
    Dong JY, Fan PD, Frizzell RA 1996. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 7:2101–12
     [Google Scholar]
  128. 128. 
    Allocca M, Doria M, Petrillo M, Colella P, Garcia-Hoyos M et al. 2008. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J. Clin. Invest. 118:1955–64
     [Google Scholar]
  129. 129. 
    Grieger JC, Samulski RJ. 2005. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J. Virol. 79:9933–44
     [Google Scholar]
  130. 130. 
    Yan Z, Sun X, Feng Z, Li G, Fisher JT et al. 2015. Optimization of recombinant adeno-associated virus-mediated expression for large transgenes, using a synthetic promoter and tandem array enhancers. Hum. Gene Ther. 26:334–46
     [Google Scholar]
  131. 131. 
    Watchko J, O'Day T, Wang B, Zhou L, Tang Y et al. 2002. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 13:1451–60
     [Google Scholar]
  132. 132. 
    Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D 2003. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108:1626–32
     [Google Scholar]
  133. 133. 
    Duan D, Yue Y, Engelhardt JF 2001. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4:383–91
     [Google Scholar]
  134. 134. 
    Yan Z, Zhang Y, Duan D, Engelhardt JF 2000. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. PNAS 97:6716–21
     [Google Scholar]
  135. 135. 
    Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD 1997. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J. Virol. 71:5932–41
     [Google Scholar]
  136. 136. 
    Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O et al. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21:704–12
     [Google Scholar]
  137. 137. 
    Corti M, Cleaver B, Clement N, Conlon TJ, Faris KJ et al. 2015. Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning. Hum. Gene Ther. Clin. Dev. 26:185–93
     [Google Scholar]
  138. 138. 
    Corti M, Elder M, Falk D, Lawson L, Smith B et al. 2014. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol. Ther. Methods Clin. Dev. 1:14033
     [Google Scholar]
  139. 139. 
    Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL et al. 2007. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13:419–22
     [Google Scholar]
  140. 140. 
    Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S et al. 2012. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 55:287–97
     [Google Scholar]
  141. 141. 
    Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA 2002. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580–90
     [Google Scholar]
  142. 142. 
    Zhu J, Huang X, Yang Y 2009. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Invest. 119:2388–98
     [Google Scholar]
  143. 143. 
    Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC et al. 2011. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117:6459–68
     [Google Scholar]
  144. 144. 
    Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ et al. 2017. Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency. PNAS 114:1655–59
     [Google Scholar]
  145. 145. 
    Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M et al. 2015. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat. Genet. 47:1187–93
     [Google Scholar]
  146. 146. 
    Berns KI, Byrne BJ, Flotte TR, Gao G, Hauswirth WW et al. 2015. Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum. Gene Ther. 26:779–81
     [Google Scholar]
  147. 147. 
    Srivastava A, Carter BJ. 2017. AAV infection: protection from cancer. Hum. Gene Ther. 28:323–27
     [Google Scholar]
  148. 148. 
    Snyder RO, Flotte TR. 2002. Production of clinical-grade recombinant adeno-associated virus vectors. Curr. Opin. Biotechnol. 13:418–23
     [Google Scholar]
  149. 149. 
    Keeler AM, ElMallah MK, Flotte TR 2017. Gene therapy 2017: progress and future directions. Clin. Transl. Sci. 10:242–48
     [Google Scholar]
  150. 150. 
    Edraki A, Mir A, Ibraheim R, Gainetdinov I, Yoon Y et al. 2019. A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing. Mol. Cell 73:4714–26
     [Google Scholar]
  151. 151. 
    Narayanan G, Cossu G, Galli MC, Flory E, Ovelgonne H et al. 2014. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union. Hum. Gene Ther. Clin. Dev. 25:1–6
     [Google Scholar]
  152. 152. 
    Flotte TR. 2015. Ethical implications of the cost of molecularly targeted therapies. Hum. Gene Ther. 26:573–74
     [Google Scholar]
  153. 153. 
    Flotte TR Keeler-Klunk AM 2018. Regulatory pathway on the manufacture & quality control of recombinant adeno-associated virus vectors. Cell Gene Ther. Insights 4:89–99
     [Google Scholar]
/content/journals/10.1146/annurev-virology-092818-015530
Loading
Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?
Annual Review of Virology 6, 601 (2019); https://doi.org/10.1146/annurev-virology-092818-015530
/content/journals/10.1146/annurev-virology-092818-015530
/content/journals/10.1146/annurev-virology-092818-015530
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error